David R. Langley

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

Min Gao, Richard E. Nettles, Makonen Belema et al. · Nature · 2010 · 937 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Selective Interactions of Cationic Porphyrins with G-Quadruplex Structures

Haiyong Han, David R. Langley, Anupama Rangan et al. · Journal of the American Chemical Society · 2001 · 320 citations

Pharmacy, Medicinal Chemistry, Molecular Biology +15

Inhibition of Hepatitis B Virus Polymerase by Entecavir

David R. Langley, Ann W. Walsh, Carl J. Baldick et al. · Journal of Virology · 2007 · 187 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 Interactions

Qi Guo, Hsu‐Tso Ho, Ira B. Dicker et al. · Journal of Virology · 2003 · 168 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh et al. · Clinical Cancer Research · 2024 · 160 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14